AGEN Agenus Inc.

3.70
+0  (3%)
Previous Close 3.60
Open 3.64
Price To book 0.00
Market Cap 363.81M
Shares 98,328,000
Volume 1,032,614
Short Ratio 8.52
Av. Daily Volume 1,243,620

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation announced April 20, 2017.
AGEN2034
Solid tumors
Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1949
Solid tumors - cancer
Phase 1/2 trial commenced June 2016
INCAGN1876
Solid tumors - cancer

Latest News

  1. First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus
  2. What's in Store for Agenus (AGEN) this Earnings Season?
  3. Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
  4. Why Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report?
  5. ETFs with exposure to Agenus, Inc. : April 10, 2017
  6. Agenus (AGEN) Sharpens Focus on Drug Development Programs
  7. Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™
  8. Blog Coverage Agenus Announced Restructuring of Business
  9. Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies
  10. ETFs with exposure to Agenus, Inc. : March 27, 2017
  11. Agenus to Participate at Two Upcoming Immuno-Oncology Conferences
  12. Agenus, Inc. :AGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  13. 4 Biotech Stocks With Jaw-Dropping Growth Potential
  14. Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : March 20, 2017
  15. Better Buy: Agenus Inc. vs. Celldex Therapeutics
  16. Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
  17. Agenus (AGEN) Reports Narrower-than-Expected Q4 Loss
  18. These 5 Stocks Under $10 Could Ignite Soon
  19. Agenus reports 4Q loss
  20. Agenus Reports Fourth Quarter and Full Year 2016 Results

SEC Filings

  1. 8-K - Current report 17771533
  2. EFFECT - Notice of Effectiveness 17732159
  3. 8-K - Current report 17723729
  4. S-3/A (Amend) - Registration statement under Securities Act of 1933 17694640
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17694538
  6. 8-K - Current report 17676918
  7. CT ORDER - Confidential treatment order 17658045
  8. D - Notice of Exempt Offering of Securities 17652124
  9. CT ORDER - Confidential treatment order 17627186
  10. 8-K - Current report 17625601